OBI Pharma Inc (浩鼎生技) has signed an agreement with Odeon Therapeutics (Hong Kong) Ltd (康騰浩諾香港生物科技) to give it the rights to two of its experimental drugs, OBI-833 and OBI-999, in China, OBI said on Tuesday.
OBI would receive US$200 million for the licensing of the cancer drugs, which includes US$12 million in newly issued Odeon shares as a signing payment, and US$188 million as development and commercialization milestone payments, the Taipei-based company said in a regulatory filing.
The drug developer would also receive double-digit percentage royalties on Odeon’s net sales of the two drugs after they are approved in China, it said.
Photo: Chen Yung-chi, Taipei Times
OBI granted Odeon exclusive rights to further develop, register and commercialize OBI-999 and OBI-833, it said, adding that the deal also includes Hong Kong and Macau.
Odeon would be responsible for all development costs, as well as subsequent regulatory and commercialization costs, it added.
The Ministry of Economic Affairs’ Investment Commission has approved the deal, OBI said.
As China’s cancer treatment market has great potential for growth, OBI and Odeon are planning to press ahead with the research and sale of the two drugs, aiming to share the commercial benefits, the filing said.
OBI-833 and OBI-999 are experimental drugs targeting Globo H, a tumor antigen that has been detected in up to 15 different cancers and has been reported to play an important role in tumor progression.
OBI-833 is a therapeutic cancer vaccine consisting of a synthetic Globo H antigen, while OBI-999 is a novel antibody drug conjugate using a Globo H antibody to target cancer cells with high Globo H expression.
“Odeon looks forward to working closely with OBI to bring these new treatment options to patients in China,” OBI chief executive officer Tim Xiao (肖汀) said in a statement.
OBI-999 has completed phase 1 trials in the US, showing excellent safety and pharmacokinetics, while OBI-333 also demonstrated great potential as an immune-oncology therapeutic vaccine, Xiao said.
OBI said that it gained local approval to conduct phase 2 clinical trial for OBI-333, expecting primary endpoint evaluation in 2024.
The Eurovision Song Contest has seen a surge in punter interest at the bookmakers, becoming a major betting event, experts said ahead of last night’s giant glamfest in Basel. “Eurovision has quietly become one of the biggest betting events of the year,” said Tomi Huttunen, senior manager of the Online Computer Finland (OCS) betting and casino platform. Betting sites have long been used to gauge which way voters might be leaning ahead of the world’s biggest televised live music event. However, bookmakers highlight a huge increase in engagement in recent years — and this year in particular. “We’ve already passed 2023’s total activity and
Nvidia Corp CEO Jensen Huang (黃仁勳) today announced that his company has selected "Beitou Shilin" in Taipei for its new Taiwan office, called Nvidia Constellation, putting an end to months of speculation. Industry sources have said that the tech giant has been eyeing the Beitou Shilin Science Park as the site of its new overseas headquarters, and speculated that the new headquarters would be built on two plots of land designated as "T17" and "T18," which span 3.89 hectares in the park. "I think it's time for us to reveal one of the largest products we've ever built," Huang said near the
BIG BUCKS: Chairman Wei is expected to receive NT$34.12 million on a proposed NT$5 cash dividend plan, while the National Development Fund would get NT$8.27 billion Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday announced that its board of directors approved US$15.25 billion in capital appropriations for long-term expansion to meet growing demand. The funds are to be used for installing advanced technology and packaging capacity, expanding mature and specialty technology, and constructing fabs with facility systems, TSMC said in a statement. The board also approved a proposal to distribute a NT$5 cash dividend per share, based on first-quarter earnings per share of NT$13.94, it said. That surpasses the NT$4.50 dividend for the fourth quarter of last year. TSMC has said that while it is eager
China yesterday announced anti-dumping duties as high as 74.9 percent on imports of polyoxymethylene (POM) copolymers, a type of engineering plastic, from Taiwan, the US, the EU and Japan. The Chinese Ministry of Commerce’s findings conclude a probe launched in May last year, shortly after the US sharply increased tariffs on Chinese electric vehicles, computer chips and other imports. POM copolymers can partially replace metals such as copper and zinc, and have various applications, including in auto parts, electronics and medical equipment, the Chinese ministry has said. In January, it said initial investigations had determined that dumping was taking place, and implemented preliminary
RSS